Given the inability to fully recapitulate the complexities of the MM BM microenvironment in vitro, the 5TGM1/KaLwRij preclinical mouse model of MM was used to further investigate a role for Grem1 in disease development and determine whether therapeutically targeting Grem1 represents a viable treatment option. This evidence concerns the gene GREM1 and Miyoshi myopathy.